source
- Study finds Lilly's obesity drug Zepbound may lower hospital and ER costs for older adultsA real‑world analysis examined older patients with obesity or excess weight who were either treated with Eli Lilly’s drug Zepbound or not. The researchers tracked healthcare utilization over time t…
- FDA clears first wearable that continuously tracks both glucose and ketone levelsThe U.S. Food and Drug Administration has authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for individuals aged two years and older who have diabetes. The device is…